Development of ²²⁵Ac Production from Low Isotopic Dilution ²²⁹Th

Area of Science:

• Nuclear medicine and radiochemistry
• Targeted alpha therapy development

Background:

• Actinium-225 (²²⁵Ac) targeted alpha therapies show significant promise for cancer treatment.
• Producing clinically relevant quantities of ²²⁵Ac has been a long-standing challenge.
• Thorium-229 (²²⁹Th) decay is a viable pathway for ²²⁵Ac production.

Purpose of the Study:

• To describe a rapid processing scheme for isolating pure ²²⁵Ac from ²²⁹Th.
• To achieve high yield and radionuclidic/radioisotopic purity of ²²⁵Ac.
• To support cancer research and development efforts with characterized ²²⁵Ac material.

Main Methods:

• Development of a rapid chemical separation process.
• Isolation of ²²⁵Ac from a ²²⁹Th source containing ²²⁸Th activity.
• Characterization of each process step and the final ²²⁵Ac product.

Main Results:

• Successful isolation of ²²⁵Ac with a high yield of 98%.
• Achieved radionuclidic and radioisotopic purity of the ²²⁵Ac.
• Detailed characterization of the ²²⁵Ac isotopic starting material was performed.

Conclusions:

• A rapid and efficient method for producing high-purity ²²⁵Ac from ²²⁹Th has been established.
• The characterized ²²⁵Ac material is suitable for advancing targeted alpha therapy research.
• This process overcomes challenges in producing ²²⁵Ac for clinical applications.